Emergent BioSolutions $40 Million Securities Settlement

If you purchased or acquired the common stock of Emergent BioSolutions Inc. (NYSE: EBS) between March 10, 2020, and November 4, 2021, you may be eligible to claim a portion of a class action settlement.

Emergent BioSolutions Inc. has agreed to pay $40,000,000 to settle a class action lawsuit for alleged violations of U.S. federal securities laws. The lawsuit claims that Emergent made false and misleading statements about the capabilities of its Bayview facility and its COVID-19 vaccine manufacturing.

Who can file a claim?

The class members eligible to file a claim include all individuals or entities who purchased or acquired Emergent common stock during the specified period. To qualify, you must have held the stock during periods when its price declined due to corrective disclosures.

• Purchased or acquired Emergent common stock between March 10, 2020, and November 4, 2021.
• Held the stock during periods when its price declined due to corrective disclosures.

Class members must submit a valid Proof of Claim to receive a payment. The deadline for submission is February 4, 2025.

Who is excluded from the class?

Certain individuals and entities are excluded from the class. These include:

• The defendants, officers, and directors of Emergent during the class period.
• Immediate family members, legal representatives, heirs, successors, and assigns of the aforementioned individuals.
• Any entity in which any defendant has or had a controlling interest.

How much can class members get?

The average recovery is estimated at $1.95 per share before deductions, but the actual amount will depend on the number of valid claims filed and the total recognized losses.

Recognized Loss Calculation: The Recognized Loss is calculated based on the difference between the purchase price and the average closing price during the 90-day lookback period following the settlement class period.

How to claim an award

To claim an award, class members must submit a Proof of Claim form. You can file a claim online or download the claim form in PDF format and mail it to the Claims Administrator.

Emergent BioSolutions Inc. Securities Settlement

c/o Strategic Claims Services

P.O. Box 230

600 N. Jackson St., Ste. 205

Media, PA 19063

Claimants need to provide proof of their transactions in Emergent common stock. This includes brokerage confirmations, monthly statements, or other documentation of transactions during the class period.

Ensure your claim is received by February 4, 2025.

$40 Million settlement fund

• Settlement Amount: $40,000,000
• Attorneys' Fees: Up to 30% of the Settlement Amount
• Litigation Expenses: Up to $500,000

• Net Settlement Fund: Remaining amount after deductions

Important dates

• Fairness Hearing: February 27, 2025
• Deadline to File a Claim: February 4, 2025

When is the Emergent BioSolutions Inc. Securities Settlement payout date?

The awards will be paid after the Court approves the settlement and any appeals are resolved. This process can take several months.

Why is there a class action settlement?

The class action lawsuit alleged that Emergent BioSolutions Inc. violated U.S. federal securities laws by making false and misleading statements about its Bayview facility's capabilities and vaccine manufacturing. The parties settled to avoid the costs and risks of further litigation.

What happens next?

After the Fairness Hearing on February 27, 2025, if the Court approves the settlement, the Claims Administrator will process the claims and distribute payments to eligible class members. Ensure your claim is submitted by the deadline to participate in the settlement.